-

Bristol Myers Squibb to Participate in the 2023 Jefferies London Healthcare Conference

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the 2023 Jefferies London Healthcare Conference in London, England, on Thursday, November 16, 2023. Tim Power, vice president, head of investor relations, will answer questions about the company during a fireside chat at 9:30 a.m. GMT (U.K.).

Investors and the general public are invited to listen to a live webcast of the session here. An archived edition of the session will be available following its conclusion.

About Bristol Myers Squibb Company

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

corporatefinancial-news

Contacts

Bristol Myers Squibb

NYSE:BMY

Release Summary
Bristol Myers Squibb to Participate in the 2023 Jefferies London Healthcare Conference
Release Versions

Contacts

More News From Bristol Myers Squibb

Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Positive Phase 3 Data from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma...

U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis

PRINCETON, N.J.--(BUSINESS WIRE)--U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis...

Bristol Myers Squibb Announces Dividend

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend...
Back to Newsroom